11/19
01:21 pm
pasg
Passage Bio (NASDAQ:PASG) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Passage Bio (NASDAQ:PASG) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
08:07 am
pasg
Passage Bio (NASDAQ:PASG) had its price target raised by analysts at Chardan Capital from $6.00 to $21.00. They now have a "buy" rating on the stock.
High
Report
Passage Bio (NASDAQ:PASG) had its price target raised by analysts at Chardan Capital from $6.00 to $21.00. They now have a "buy" rating on the stock.
11/10
05:12 pm
pasg
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
High
Report
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
11/10
04:15 pm
pasg
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
High
Report
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
11/5
07:00 am
pasg
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Low
Report
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
10/14
07:53 am
pasg
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference [Yahoo! Finance]
Low
Report
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference [Yahoo! Finance]
10/14
07:00 am
pasg
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
Medium
Report
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference